imperatorin has been researched along with Angiogenesis, Pathologic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jin, X; Li, MY; Li, X; Ma, J; Mi, C; Piao, LX; Quan, ZS; Wang, KS; Wang, Z; Xu, GH; Zuo, HX | 1 |
1 other study(ies) available for imperatorin and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Imperatorin suppresses proliferation and angiogenesis of human colon cancer cell by targeting HIF-1α via the mTOR/p70S6K/4E-BP1 and MAPK pathways.
Topics: Adaptor Proteins, Signal Transducing; Angelica; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Cell Cycle Proteins; Cell Proliferation; Colonic Neoplasms; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Furocoumarins; HCT116 Cells; HeLa Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Phosphoproteins; Ribosomal Protein S6 Kinases, 70-kDa; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2017 |